口服Paltusotine治疗生化未控制肢端肥大症的快速持续应答
这项3期随机双盲安慰剂对照试验纳入111例未接受药物治疗的肢端肥大症患者,评估每日一次口服Paltusotine的疗效与安全性。24周时Paltusotine组IGF-I正常化率55.6%显著高于安慰剂组5.3%(OR 42.81,95%CI 8.44-455.82,P<.0001),且4周内92.6%患者IGF-I下降。Paltusotine快速持续降低IGF-I、改善症状且耐受性良好。
要点
- Paltusotine 24周IGF-I正常化率55.6% vs 安慰剂5.3%,优势显著。
- 92.6%患者4周内IGF-I下降,起效迅速。
- 不良反应多为肢端肥大症症状或轻度短暂胃肠道反应。
核心结论
- Paltusotine治疗未控制肢端肥大症患者,IGF-I正常化率显著高于安慰剂。
- Paltusotine与快速持续IGF-I降低、症状显著改善及垂体瘤稳定或缩小相关,且耐受性良好。
研究设计与样本
- 3期随机双盲安慰剂对照试验,纳入111例未接受药物治疗的肢端肥大症成人患者。
- 分层1(n=82):未用药或停药≥4个月且IGF-I≥1.3×ULN;分层2(n=29):生长抑素受体配体控制后洗脱且IGF-I升高≥30%至≥1.1×ULN。
- 患者随机接受Paltusotine(n=54)或安慰剂(n=57)治疗24周。
主要发现
- 24周IGF-I正常化率:Paltusotine组55.6% vs 安慰剂组5.3%(OR 42.81;95%CI 8.44-455.82;P<.0001),两个分层均优。
- 4周内92.6%的Paltusotine治疗患者IGF-I下降。
- IGF-I平均变化(±SE):Paltusotine组-0.82±0.08×ULN vs 安慰剂组0.09±0.08×ULN(P<.0001)。
- IGF-I<1.3×ULN比例:66.7% vs 14.0%(OR 18.32;95%CI 5.64-79.16;P<.0001)。
- GH(5次均值)<1.0 ng/mL比例:57.4% vs 17.5%(OR 7.59;95%CI 2.78-23.48;P<.0001)。
关键数值与推荐
- 主要终点为24周IGF-I正常化率。
- 次要终点包括IGF-I变化、IGF-I<1.3×ULN比例、GH<1.0 ng/mL比例及症状日记评分变化。
临床怎么用
- Paltusotine可作为未接受药物治疗的生化未控制肢端肥大症患者的每日一次口服治疗选择。
- 治疗4周内即可观察到IGF-I下降,需关注早期疗效评估。
- 常见不良反应为肢端肥大症症状或轻度短暂胃肠道反应,如腹泻、腹痛。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Paltusotine is a nonpeptide, selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly. OBJECTIVE: To evaluate efficacy and safety of paltusotine in patients with biochemically uncontrolled acromegaly not currently receiving medical therapy. METHODS: In this phase 3, randomized, double-blind, placebo-controlled trial, adults with medically untreated acromegaly at randomization (stratum 1: medication-naïve or off acromegaly medications ≥4 months [IGF-I ≥ 1.3 × upper limit of normal {ULN}]; stratum 2: controlled on a somatostatin receptor ligand and underwent washout [IGF-I increase ≥30% to ≥1.1 × ULN]) received paltusotine or placebo for 24 weeks. RESULTS: A total of 111 patients (stratum 1, n = 82; stratum 2, n = 29) enrolled (paltusotine, n = 54; placebo, n = 57). The primary endpoint of IGF-I normalization at 24 weeks was met in 55.6% of paltusotine-treated patients vs 5.3% for placebo (odds ratio [OR]: 42.81; 95% CI, 8.44-455.82; P < .0001), with superiority to placebo in both strata. Paltusotine treatment decreased IGF-I in 92.6% of patients within the first 4 weeks. All secondary endpoints were met: mean (±SE) change in IGF-I of -0.82 ± 0.08×ULN with paltusotine vs 0.09 ± 0.08×ULN with placebo (P < .0001); IGF-I < 1.3×ULN in 66.7% vs 14.0% of patients (OR: 18.32; 95% CI, 5.64-79.16; P < .0001); GH (5-sample mean) < 1.0 ng/mL in 57.4% vs 17.5% (OR: 7.59; 95% CI, 2.78-23.48; P < .0001); mean (±SE) change in Acromegaly Symptom Diary score of -2.7 ± 1.4 vs 2.8 ± 1.4 (P = .004). Most adverse events were acromegaly symptoms or mild, transitory gastrointestinal effects characteristic of somatostatin receptor ligands (eg, diarrhea, abdominal pain). Pituitary tumor volume was stable or reduced in paltusotine-treated patients. CONCLUSION: IGF-I normalized in significantly more patients with uncontrolled acromegaly treated with paltusotine vs placebo. Paltusotine was associated with rapid, sustained IGF-I reduction, significant symptom improvement and stable or reduced pituitary tumor size and was well tolerated.
引用
- Biller BMK, Casagrande A, Elenkova A, et al. Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment. J Clin Endocrinol Metab. 2026. PMID: 41128642. doi:10.1210/clinem/dgaf579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。